Pre-Open Stock Movers 05/13: (AMRK) (SI) (SONO) Higher; (WISH) (POSH) (TDUP) Lower (more...)

May 13, 2021 9:28 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Today's Pre-Open Stock Movers:

Silvergate Capital Corporation (NYSE: SI) 16% HIGHER; announced a partnership with Diem Networks U.S. Inc., in which the Company’s wholly-owned subsidiary Silvergate Bank will become the exclusive issuer of Diem USD.

A-Mark Precious Metals, Inc. (NASDAQ: AMRK) 18.7% HIGHER; A-Mark reported over $2 billion in revenue and record earnings in its fiscal third quarter, boosted by strong market conditions and the completion of the most significant acquisition in its history

Sonos (NASDAQ: SONO) 14.8% HIGHER; reported Q2 EPS of $0.31, $0.53 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $332.9 million versus the consensus estimate of $248.41 million. Sonos sees FY2021 revenue of $1.625-1.675 billion, versus the consensus of $1.56 billion.

ContextLogic (NASDAQ: WISH) 13.3% LOWER; reported Q1 revenue of $772 million versus the consensus estimate of $743.09 million. ContextLogic sees Q2 2021 revenue of $715-730 million, versus the consensus of $759.13 million.

Poshmark Inc. (NASDAQ: POSH) 12.4% LOWER; reported Q1 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $81 million versus the consensus estimate of $77.18 million. Poshmark Inc. sees Q2 2021 revenue of $79-81 million, versus the consensus of $79.3 million. Adjusted EBITDA range: $1.5 million - $2.5 million.

Vroom (NASDAQ: VRM) 10.9% HIGHER; reported Q1 EPS of ($0.57), $0.06 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $591.1 million versus the consensus estimate of $518.19 million. Vroom sees Q2 2021 EPS of ($0.58)-($0.51), versus the consensus of ($0.44). Vroom sees Q2 2021 revenue of $618-640 million, versus the consensus of $600.81 million. For the full year 2021, we continue to expect triple digit year-over-year growth in ecommerce unit sales and more than 200% year-over-year growth in aggregate gross profit.

ThredUp Inc. (Nasdaq: TDUP) 7.8% LOWER; Record quarterly revenue of $56 million

Funko (NASDAQ: FNKO) 7.8% HIGHER; BofA Securities upgraded from Underperform to Buy, PT $30.00 (from $12.00).

1Life Healthcare (NASDAQ: ONEM) 6.9% LOWER; reported Q1 EPS of ($0.29), $0.14 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $121.4 million versus the consensus estimate of $116.24 million. 1Life Healthcare sees Q2 2021 revenue of $111-118 million, versus the consensus of $117.4 million. 1Life Healthcare sees FY2021 revenue of $465-485 million, versus the consensus of $482.44 million.

Marathon Digital Holdings, Inc. (NASDAQ: MARA) 7% LOWER; Bitcoin stocks are prices down 10% on Elon Musk's U-turn on accepting Bitcoin to buy Tesla vehicles.

Riot Blockchain, Inc. (NASDAQ: RIOT) 6.5% LOWER; Bitcoin stocks are prices down 10% on Elon Musk's U-turn on accepting Bitcoin to buy Tesla vehicles.

GrowGeneration Corp. (NASDAQ: GRWG) 6.3% HIGHER; reported Q1 EPS of $0.10, $0.03 better than the analyst estimate of $0.07. Revenue for the quarter came in at $90 million versus the consensus estimate of $87.14 million.

Boot Barn Holdings (NYSE: BOOT) 6.2% HIGHER; reported Q4 EPS of $0.75, $0.28 better than the analyst estimate of $0.47. Revenue for the quarter came in at $258.9 million versus the consensus estimate of $232.86 million.

MicroStrategy Incorporated (NASDAQ: MSTR) 5.2% LOWER; Bitcoin stocks are prices down 10% on Elon Musk's U-turn on accepting Bitcoin to buy Tesla vehicles.

Fluor Corporation (NYSE: FLR) 4.8% LOWER; Intends to offer in a private placement, subject to market and other conditions, 450,000 shares of a newly created series of convertible preferred stock, to be designated as Series A Cumulative Perpetual Convertible Preferred Stock (the Preferred Stock).

Heron Therapeutics, Inc. (Nasdaq: HRTX) 2.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. ZYNRELEF, the first and only extended-release dual-acting local anesthetic (DALA), delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. The synergy between bupivacaine and meloxicam in ZYNRELEF has resulted in patients experiencing significantly less pain, including severe pain, and significantly more patients requiring no opioids (opioid-free) after surgery as compared to bupivacaine solution, the current standard-of-care.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Tesla, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Bitcoin, Pre Market Movers, FDA